[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"LMC Diabetes & Endocrinology Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":119},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,75,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100625576","real-world-canadian-retrospective-study-evaluating-longitudinal-semaglutide-use-on-cardio-kidney-metabolic-outcomes-100625576",false,"NCT07424430","Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes","Real-world Canadian Retrospective Study Evaluating Longitudinal SEMAglutide Use on Cardio-Kidney-Metabolic Outcomes","SEMA-CKM","Inclusion Criteria:\n\nT2D Cohort:\n\n* A clinical diagnosis of T2D ≥ 1 year\n* HbA1c ≥ 6.5% (pre-index date)\n* Initiated semaglutide or other AHA(s) before January 1st, 2023\\*\n* Seen by an LMC endocrinologist in the last 18 months as of the query date\n* ≥ one HbA1c value up to 6 months (+ 90 days) prior to index date\n* Informed data consent for their medical record data to be used for research purposes\n\nObesity Cohort:\n\n* 18 years or older\n* BMI ≥ 27 kg\u002Fm2\n* HbA1c \\\u003C 6.5% (pre-index date)\n* Initiated semaglutide before January 1st, 2023\\*\n* Seen by an LMC endocrinologist in the last 18 months as of the query date\n* ≥ one HbA1c value up to 6 months (± 90 days) prior to index date\n* Informed data consent for their medical record data to be used for research purposes\n\nExclusion Criteria:\n\n* Clinical diagnosis of type 1 diabetes\u002Flatent autoimmune diabetes in adults (LADA)\n* Clinical diagnosis of T2D (obesity cohort only)\n* Are pregnant at the time of semaglutide or other AHA initiation or became pregnant during follow-up period\n* Documented history or family history of medullary thyroid carcinoma\n* Participation in a research study with an Investigational Product\n* eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m2 at index date\n* Use of non-semaglutide GLP-1-based medication for more than 6 months after the index date (T2D sema cohort and obesity sema cohort)\n* Use of other AHA for more than 6 months after the index date within the first year of semaglutide use (T2D sema cohort and obesity sema cohort)","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","OBSERVATIONAL","The goal of this study is to better understand the real-world effectiveness of semaglutide use on cardio-kidney-metabolic outcomes among adults with T2D and adults with obesity (without diabetes mellitus). This is a retrospective longitudinal analysis using the LMC Diabetes Registry. The primary outcome of the study is to evaluate the change in HbA1c between baseline to 3 years of follow-up among adults with T2D who initiated semaglutide compared to adults with T2D who initiated other AHAs, including sulfonylurea, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors.",[25,26,27],"Diabetes (DM)","Type 2 Diabetes","Obesity (Disorder)",[29,30,31,32],"semaglutide","T2D","AHA","HbA1c","NOT_YET_RECRUITING","2026-02-13",{"date":36,"type":37},"2026-02-20","ACTUAL",{"date":39,"type":21},"2026-03",{"date":41,"type":21},"2026-05",{"name":43,"class":44},"LMC Diabetes & Endocrinology Ltd.","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100605043","remission-of-type-2-diabetes-between-intermittently-scanned-continuous-glucose-monitoring-and-capillary-blood-glucose-monitoring-when-added-to-low-calorie-meal-replacement-and-diabetes-self-management-education-100605043","NCT07157384","REMIssion of Type 2 Diabetes Between Intermittently Scanned Continuous Glucose Monitoring and Capillary Blood Glucose Monitoring When Added to Low-calorie Meal Replacement and Diabetes Self-management Education","Randomized Controlled Trial Comparing REMIssion of Type 2 Diabetes Between Intermittently Scanned Continuous Glucose Monitoring and Capillary Blood Glucose Monitoring When Added to Low-calorie Meal Replacement and Diabetes Self-management Education: The REMIT2D isCGM Trial","REMIT2D isCGM","Inclusion Criteria:\n\n* Age 18-75 years old\n* T2D treated with ≤ 3 non-insulin antihyperglycemic agents\n* A clinical diagnosis of T2D for \\> 6 months and ≤ 6 years ago\n* HbA1c 6.0-9.0% on 2 or 3 antihyperglycemic agents, HbA1c 6.5-9.0% on 1 antihyperglycemic agent, or HbA1c 7.0-9.0% on 0 antihyperglycemic agents\n* BMI 27-44.9 kg\u002Fm2\n* Not currently using a real-time CGM or isCGM\n* Willing to adhere to LCMR and initiate isCGM or CBG monitoring, and capable to do so as judged by investigator\n\nExclusion Criteria:\n\n* Current or prior use of insulin (except for prior management of gestational diabetes mellitus)\n* Are pregnant or breastfeeding, or planning to become pregnant in the next 2 years\n* Severe or progressive retinopathy\n* Have a history of cardiovascular disease: coronary artery disease (CAD): prior myocardial infarction, previous unstable angina, documented CAD on angiography with stenosis \\>50%, imaging evidence of myocardial ischemia, coronary revascularization), peripheral arterial disease (lower extremity stenosis exceeding 50%, previous limb angioplasty, stenting or bypass surgery; or previous limb or foot amputation due to circulatory insufficiency or ankle brachial index of \\\u003C 0.9 in at least one limb.), cerebrovascular disease (history of ischemic or hemorrhagic stroke or \\> 50% carotid stenosis), or heart failure\n* Chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C 60 ml\u002Fmin\u002F1.73 m2 or eGFR 60-90 ml\u002Fmin\u002F1.73 m2 with urine albumin to creatinine ratio (uACR) \\> 20 mg\u002Fmmol (any previously resolved macroalbuminuria will be considered as a reason for ineligibility, at the investigator's discretion)\n* Active binge eating disorder or other eating disorder\n* Uncontrolled mental health disorder\n* Current use of atypical antipsychotic or corticosteroid\n* Use of other implanted medical devices, such as pacemakers\n* Participant whose circumstance is deemed by investigator to be unadvisable, unsafe, or unlikely to be capable of adhering to LCMR and\u002For isCGM\u002FCBG monitoring during the study period","75 Years",{"count":55,"type":21},176,"INTERVENTIONAL",[58],"NA","The goal of the study is to evaluate the effectiveness of intermittently scanned continuous glucose monitoring compared to capillary blood glucose monitoring among people with type 2 diabetes initiating low calorie meal replacement plus diabetes self-management education in improving the proportion of patients achieving remission of type 2 diabetes. This is an open-label randomized controlled trial with 2 treatment arms randomized in a 1:1 manner.\n\nThe Investigators hypothesize that the use of intermittently scanned continuous glucose monitoring will improve the percentage of participants achieving remission of type 2 diabetes (remission to prediabetes or remission to normoglycemia), among adults with type 2 diabetes starting low calorie meal replacement and diabetes self-management education compared to a control group using capillary blood glucose monitoring at 18-30 weeks follow-up (end of Phase 2).\n\nThe primary outcome of the study is to compare the percentage of participants who achieve remission of type 2 diabetes (remission to prediabetes with HbA1c 6.0% to 6.4% or remission to normoglycemia with HbA1c \\\u003C 6.0% using no antihyperglycemic agents for ≥ 3 consecutive months) at 18-30 weeks follow-up between intermittently scanned continuous glucose monitoring vs. capillary blood glucose monitoring, when combined with low calorie meal replacement and diabetes self-management education.\n\nParticipants in both arms complete 3 phases of the study. Phase 1: total dietary replacement, Phase 2: food re-introduction and Phase 3: remission, while receiving diabetes self-management education sessions over a span of 18 months.",[26],[62,63,64,65],"low-calorie meal replacement","remission","intermittently scanned continuous glucose monitoring","type 2 diabetes","2025-08-28",{"date":68,"type":37},"2025-09-05",{"date":70,"type":21},"2025-09",{"date":72,"type":21},"2027-06",{"name":43,"class":44},6,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":85,"studyType":22,"phases":4,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":98,"locationsCount":99},"100580423","real-world-effects-of-using-intermittently-scanned-continuous-glucose-monitoring-and-pharmacist-led-coaching-on-the-management-of-type-2-diabetes-among-adults-not-using-insulin-real-iscgm-t2d-100580423","NCT06837103","Real-world Effects of Using Intermittently Scanned Continuous Glucose Monitoring and Pharmacist-led Coaching on the Management of Type 2 Diabetes Among Adults Not Using Insulin (REAL isCGM T2D)","Real-world Effects of Using Intermittently Scanned Continuous Glucose Monitoring and Pharmacist-led Coaching on the Management of Type 2 Diabetes Among Adults Using Non-insulin Antihyperglycemic Agents","REAL isCGM T2D","Inclusion Criteria:\n\n* 18 years or older\n* Clinical diagnosis of T2D ≥ one year\n* Using at least one AHA\n* Status as a Sun Life group benefits member, initiates isCGM device through Lumino Health™ Pharmacy, and completes one initial pharmacist consultation (isCGM cohort) or completes 2 or more diabetes coaching program consultations (isCGM+coaching cohort); or has private health insurance and uses CBG monitoring (CBG cohort)\n* Baseline HbA1c ≥ 7.0%\n* ≥ 1 HbA1c value up to 6 months prior to index date\n* Exclusive use of isCGM for ≥ 3 months\n* Informed consent\n\nExclusion Criteria:\n\n* Have a history of insulin use\n* Are pregnant or breastfeeding at the time of study enrollment or become pregnant during the study\n* Have an estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin\u002F1.73m2\n* Previously used rtCGM or isCGM for \\> 3 months\n* Recent or expectant change to antihyperglycemic medications or doses within 30 days of index date",{"count":84,"type":21},250,"6 Months","The goal of this prospective study is to evaluate diabetes outcomes after initiating second generation intermittently scanned continuous glucose monitoring (isCGM) plus one pharmacist consultation session compared with capillary blood glucose (CBG) monitoring among insulin-naïve adults with type 2 diabetes (T2D) in a specialist endocrinology clinical setting in Canada.\n\nPrimary Outcome - To evaluate change in HbA1c at 3-6 months follow-up after initiating isCGM plus one pharmacist consultation (isCGM cohort) compared with CBG monitoring (CBG cohort) among insulin-naïve adults with T2D.\n\nSecondary Outcomes - To determine the change in metabolic outcomes and patient reported outcomes (PROs) and number of non-insulin antihyperglycemic agents (AHAs) prescribed from baseline to 3-6 months (± 6 weeks) in the isCGM cohort compared to the CBG cohort. Another secondary outcome is to assess isCGM metrics and number of isCGM discontinuations in the isCGM cohort at 3-6 months (± 6 weeks) compared to baseline. Additionally the study will describe and\u002For evaluate glycemic and metabolic outcomes, and PROs in participants who initiate an isCGM device and opt to enroll in a diabetes coaching program (isCGM+coaching cohort) at baseline compared to follow-up at 3-6 months (± 6 weeks).\n\nExploratory Outcomes - To compare change in HbA1c between the matched isCGM cohort and CBG cohort by subgroups: age (\\\u003C 65 years old vs ≥ 65 years old) and baseline HbA1c (\\\u003C 8.5% vs ≥ 8.5%).",[26],[89,65,90,32],"continuous glucose monitoring","time in range","RECRUITING","2025-04-30",{"date":94,"type":37},"2025-05-04",{"date":96,"type":37},"2025-04-09",{"date":41,"type":21},{"name":43,"class":44},1,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":108,"targetDuration":85,"studyType":22,"phases":4,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":113,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":99},"100578014","effect-of-switching-from-intermittently-scanned-to-real-time-continuous-glucose-monitoring-on-diabetes-management-in-adults-with-type-2-diabetes-switch-cgm-t2d-100578014","NCT06805786","Effect of Switching From Intermittently Scanned to Real-time Continuous Glucose Monitoring on Diabetes Management in Adults With Type 2 Diabetes (Switch CGM T2D)","Effect of Switching From Intermittently Scanned Continuous Glucose Monitoring to Real-time Continuous Glucose Monitoring on Glycemic Outcomes in Adults With Type 2 Diabetes","Switch CGM T2D","Inclusion Criteria:\n\n* 18 years or older\n* Clinical diagnosis of T2D ≥ one year\n* Using insulin for ≥ 6 months\n* Continued FreeStyle Libre® 2 isCGM device (isCGM cohort) as of the study start date\n* Would like to switch from a FreeStyle Libre® 2 isCGM device to a Dexcom® G7 rtCGM device (rtCGM switch cohort) as of the study start date\n* Baseline HbA1c ≥ 7.5%\n* Known rtCGM\u002FisCGM start date (month and year)\n* Exclusive use of isCGM for ≥ 3 months\n* Data on LibreView platforms have percent sensor capture ≥ 70% for 14 days of available data up to 6 months prior to index date\n* ≥ 1 value for TIR (%) up to 6 months (± 6 weeks) prior to index date\n* ≥ 1 value for HbA1c (%) up to 6 months (± 6 weeks) prior to index date\n* Data consent\n\nExclusion Criteria:\n\n* Have a prior history of rtCGM within 12 months of the index date\n* Recent or expectant change to antihyperglycemic medications or doses within 30 days of index date\n* Recent or expectant titration of insulin dose ≥ 20% within 30 days of index date\n* Are pregnant at the time of study enrollment or intending to become pregnant during the study\n* Used the isCGM or rtCGM for \\\u003C 3 months\n* Using continuous subcutaneous insulin infusion",{"count":109,"type":21},150,"The goal of this prospective study is to evaluate diabetes outcomes and patient experience following a switch from second generation intermittently scanned continuous glucose monitor (isCGM) to real-time continuous glucose monitor (rtCGM) compared with participants with continued isCGM use among adults with insulin-treated type 2 diabetes (T2D) in a specialist endocrinology clinic setting in Canada. The study aims include:\n\nPrimary outcome - Evaluate change in percent time in range (TIR) at 3-6 months follow-up after switching from a second generation isCGM system to a rtCGM system compared with participants with continued second generation isCGM use.\n\nSecondary outcomes - Compare glycemic and metabolic outcomes (ie. additional CGM metrics, HbA1c, and weight), and outcomes related to diabetes management (ie. self-reported hypoglycemia and change in total daily dose \\[TDD\\] of insulin) at 3-6 months follow-up in the rtCGM switch and isCGM cohorts among adults with insulin-treated T2D.\n\nExploratory outcomes - Evaluate patient-reported outcomes (PROs) in the rtCGM switch cohort only. PROs will include questions about device satisfaction and psychological distress at baseline and 3-6 months follow-up, and protocol-specific questions about Dexcom Care following use of the rtCGM device at 3-6 months follow-up. Additionally this study will compare percent TIR, percent TBR, percent TAR, and HbA1c between rtCGM switch and isCGM cohorts by insulin therapy subgroup (basal vs MDI therapy).\n\nrtCGM switch participants will be enrolled at an LMC location and asked to complete PROs at baseline and 3-6 month follow-up. Continued isCGM participants will not be asked to complete PROs.",[26],[65,89,32,90],{"date":94,"type":37},{"date":115,"type":37},"2025-02-11",{"date":117,"type":21},"2026-07",{"name":43,"class":44},""]